| Code | 0312E | ||||||||||
| MA number | 09/0086/22-S | ||||||||||
| Product Form: | cps end 56x40 mg (fľ.HDPE) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Medreg s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 09 - ANTACIDA (VRÁTANE ANTIULCEROSNYCH LIEČIV) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 28.04.2022 |
| Validity: | 28.04.2027 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Omeprazol Medreg_02_2025.pdf
|
| SPC: |
SPC_Omeprazol Medreg_02_2025.pdf
|
| Safety feature | Yes |
| Data update: | 29.04.2022 |
